What are the long-term benefits of giving metformin to a patient with metabolic syndrome?
Metadata[+] Show full item record
Metformin treatment decreases fasting glucose levels, decreases body mass index (BMI), and increases high-density lipoprotein (HDL) in patients with the metabolic syndrome. (SOR: C, based on a meta-analysis using intermediate outcomes.) Over several years, metformin treatment is associated with a small decrease in the number of patients continuing to meet the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III criteria for metabolic syndrome. (SOR: B, based on 1 prospective cohort study.) Shorter term use (3 months) is not associated with reversal of metabolic syndrome. (SOR: B, based on 1 RCT.)
Evidence Based Practice 15(1): 12.